Can You Take Evenity (Romosozumab) with PPIs Like Omeprazole or Pantoprazole?

No Direct Pharmacokinetic Interaction Exists

Romosozumab and PPIs operate through entirely separate pharmacologic pathways, so co-administration does not produce a classical drug-drug interaction. The concern with this combination is indirect: PPIs compromise the calcium and bone metabolism environment that romosozumab depends on to build bone.

How Romosozumab Is Cleared

Romosozumab is a humanized IgG2 monoclonal antibody that binds sclerostin, a glycoprotein secreted by osteocytes that normally inhibits the Wnt signaling pathway in osteoblasts. The Evenity prescribing information confirms that, like other monoclonal antibodies, romosozumab is eliminated through target-mediated disposition and intracellular proteolytic catabolism. It does not undergo cytochrome P450 metabolism, is not a substrate or inhibitor of P-glycoprotein, and is not renally excreted as intact drug [1]. Its estimated half-life is 12.8 days after subcutaneous injection.

Why PPIs Don't Alter Romosozumab Levels

PPIs (omeprazole, pantoprazole, lansoprazole, esomeprazole) suppress gastric acid by irreversibly inhibiting the H⁺/K⁺-ATPase proton pump on parietal cells. Their drug interaction profile centers on CYP2C19 and CYP3A4 inhibition, reduced gastric pH affecting pH-dependent oral drug absorption, and competition for renal tubular secretion [2]. None of these mechanisms apply to a subcutaneously injected monoclonal antibody. The FDA label for Evenity lists no contraindicated or cautioned co-medications, and neither the Lexicomp nor Clinical Pharmacology DDI databases flag a romosozumab-PPI pair [1].

That absence of a direct interaction, though, is only half the clinical picture.

The Real Risk: PPIs Undermine the Bone You Are Trying to Build

The reason clinicians should still pay attention to this combination is pharmacodynamic. Romosozumab produces its largest bone mineral density (BMD) gains during a single 12-month course. Any concurrent factor that accelerates bone resorption or impairs mineral substrate supply can blunt that therapeutic window.

PPI-Associated Fracture Risk

A 2019 meta-analysis of 18 observational studies (N = 244,109 fracture cases) published in Osteoporosis International found that PPI use was associated with a 26% increase in hip fracture risk (pooled OR 1.26, 95% CI 1.18 to 1.35) and a 20% increase in vertebral fracture risk [3]. The risk was duration-dependent: use beyond one year carried higher point estimates than shorter courses. A separate Canadian Multicentre Osteoporosis Study cohort analysis (N = 9,423, mean follow-up 10 years) reported a 40% higher hip fracture rate in continuous PPI users compared with non-users (HR 1.40, 95% CI 1.11 to 1.77) [4].

Impaired Calcium Absorption

Gastric acid is required for the dissolution and ionization of calcium carbonate, the most commonly prescribed supplemental calcium salt. A crossover study by Graziani et al. Demonstrated that omeprazole 20 mg daily reduced fractional calcium absorption from calcium carbonate by approximately 40% in fasting elderly subjects [5]. The FDA label for omeprazole notes the risk of hypomagnesemia and mentions bone fracture risk with long-term use [2].

Calcium citrate, by contrast, does not require gastric acid for absorption. A study published in the Journal of Clinical Pharmacology confirmed that calcium citrate bioavailability was unaffected by achlorhydria or concurrent PPI therapy [6]. This distinction has direct prescribing relevance for patients on both romosozumab and a PPI.

Vitamin D and Magnesium Depletion

PPIs also reduce magnesium absorption in a subset of patients, with FDA-reported cases of symptomatic hypomagnesemia requiring hospitalization after as few as 3 months of therapy [2]. Low magnesium impairs parathyroid hormone (PTH) secretion and reduces 1,25-dihydroxyvitamin D activation, creating a downstream calcium deficit. Because romosozumab can cause transient hypocalcemia (reported in 0.4% of patients in the FRAME trial), stacking a PPI-driven mineral deficit on top of romosozumab-induced calcium demand is clinically undesirable [1].

What the Key Romosozumab Trials Show

The two registration trials for romosozumab did not exclude PPI users, but neither trial published a pre-specified subgroup analysis by PPI status.

FRAME Trial (N = 7,180)

The FRAME trial randomized postmenopausal women with osteoporosis (T-score −2.5 to −3.5) to romosozumab 210 mg SC monthly or placebo for 12 months, followed by denosumab in both arms. At 12 months, romosozumab produced an 13.3% increase in lumbar spine BMD versus 0.0% for placebo [7]. New vertebral fracture incidence was 73% lower in the romosozumab group (0.5% vs. 1.8%, P<0.001) [7]. The trial enrolled a real-world population likely to include PPI users (median age 71), but concomitant medication data by drug class were not separately reported.

ARCH Trial (N = 4,093)

ARCH compared romosozumab followed by alendronate versus alendronate alone. Romosozumab-to-alendronate reduced new vertebral fracture risk by 48% at 24 months (6.2% vs. 11.9%, P<0.001) [8]. The ARCH trial's cardiovascular safety signal (higher adjudicated MACE in the romosozumab arm during the first 12 months) led to the FDA boxed warning, but no PPI-specific adverse-event signal was identified [1][8].

Because no subgroup data exist, clinicians must rely on the known independent effects of PPIs on bone and calcium metabolism to guide risk assessment. The absence of evidence of harm is not evidence of absence, especially in a population already at high fracture risk.

Monitoring Protocol When Co-Prescribing

A structured monitoring approach reduces the chance that PPI-related mineral deficits silently erode romosozumab efficacy.

Baseline Labs (Before First Romosozumab Dose)

Check serum calcium (corrected for albumin), 25-hydroxyvitamin D, serum magnesium, and intact PTH. The Evenity label requires correcting hypocalcemia before initiation [1]. If vitamin D is below 30 ng/mL, load with 50,000 IU ergocalciferol weekly for 8 weeks before starting romosozumab.

During the 12-Month Course

Recheck serum calcium and magnesium at months 1, 6, and 12. If the patient is on a PPI, add a month-3 magnesium level. Any magnesium below 1.8 mg/dL warrants oral magnesium glycinate supplementation (400 mg elemental daily) and a PPI step-down conversation.

DXA Timing

Obtain a follow-up DXA at 12 months (end of romosozumab course) to quantify BMD response. The ISCD 2019 position statement supports repeat DXA at 1 to 2 years during anabolic therapy to assess treatment response [9]. If BMD gains are below expected (less than 5% lumbar spine increase), investigate PPI duration and calcium absorption as potential contributors.

Practical Dose-Adjustment and Counseling Strategies

No dose adjustment of either romosozumab or the PPI is pharmacokinetically required. The adjustments below are pharmacodynamic risk-mitigation strategies.

Step Down the PPI If Possible

The American Gastroenterological Association (AGA) 2017 best-practice advice recommends that patients on long-term PPIs undergo periodic reassessment and step-down to the lowest effective dose or an H2-receptor antagonist (famotidine 20 mg BID) when clinically appropriate [10]. During a 12-month romosozumab course, this reassessment is especially warranted. Patients using PPIs for uncomplicated GERD or empiric dyspepsia are the best candidates for de-escalation.

Switch Calcium Supplement Form

If the PPI cannot be discontinued, switch from calcium carbonate to calcium citrate 600 mg twice daily with meals. Calcium citrate's acid-independent absorption bypasses the PPI-induced achlorhydria problem entirely [6].

Ensure Adequate Vitamin D

Prescribe cholecalciferol 2,000 to 4,000 IU daily (or a dose sufficient to maintain 25-OH-D above 30 ng/mL) throughout the romosozumab course. Vitamin D facilitates active intestinal calcium transport via TRPV6 channels, partially compensating for the passive absorption deficit caused by PPIs [11].

Counsel on Timing

While romosozumab injection timing is not affected by PPI dosing (romosozumab is subcutaneous, PPIs are oral), patients should take calcium citrate with food and separate it from any oral bisphosphonate they may transition to after romosozumab. PPIs should be taken 30 to 60 minutes before breakfast per standard labeling [2].

Special Populations

Patients with Barrett Esophagus or Erosive Esophagitis

These patients have a strong indication for continued PPI therapy at full dose. Stepping down to an H2-blocker is not appropriate. In this scenario, maximize calcium citrate, vitamin D, and magnesium supplementation and monitor labs more frequently (months 1, 3, 6, 9, 12).

Patients on Chronic Corticosteroids

Glucocorticoids independently accelerate bone loss and are a common reason for concurrent PPI use (gastroprotection). The triple combination of a corticosteroid, a PPI, and romosozumab demands the most aggressive mineral repletion. Consider referral to endocrinology for co-management.

Elderly Patients (Age 75+)

Achlorhydria prevalence increases with age, and PPI use compounds baseline calcium malabsorption. The FRAME trial's benefit was consistent across age subgroups, but older patients had lower absolute BMD gains [7]. Prioritize calcium citrate and ensure protein intake exceeds 1.0 g/kg/day, as protein supports the collagen matrix that romosozumab's osteoblast stimulation builds upon.

After Romosozumab: Sequencing Considerations

Romosozumab is approved for a single 12-month course only. BMD gains are rapidly lost without a follow-on antiresorptive agent, typically denosumab or a bisphosphonate [7][8].

Transitioning to Oral Bisphosphonates

If the patient transitions to alendronate or risedronate after romosozumab, the PPI interaction profile changes. Oral bisphosphonates require an acidic gastric environment for dissolution (though their absorption is inherently poor at approximately 1%). A 2012 nested case-control study in Calcified Tissue International (N = 24,382) found that concurrent PPI use with oral bisphosphonates was associated with a 50% attenuation of the bisphosphonate's fracture-reduction benefit (adjusted OR for hip fracture 1.50, 95% CI 1.01 to 2.23) [12]. This makes the PPI step-down conversation even more pressing at the transition point.

Transitioning to Denosumab

Denosumab, like romosozumab, is a subcutaneous monoclonal antibody (anti-RANKL) and has no pharmacokinetic interaction with PPIs. The pharmacodynamic calcium concern persists, because denosumab also suppresses osteoclast-mediated calcium release from bone, occasionally causing hypocalcemia [13]. Continue calcium citrate and vitamin D supplementation throughout denosumab therapy.

Severity Rating and Clinical Bottom Line

Per Lexicomp and Clinical Pharmacology databases, the romosozumab-PPI pair carries no formal interaction severity rating because there is no direct pharmacokinetic interaction [1][2]. The pharmacodynamic concern (PPI-associated fracture risk and calcium malabsorption undermining anabolic bone therapy) is a clinical-judgment issue, not a system-flagged DDI.

For prescribers: document the PPI indication, attempt step-down when appropriate, switch to calcium citrate, replete vitamin D and magnesium, and monitor labs at baseline and during the 12-month romosozumab course. These measures cost little and protect the substantial BMD investment that romosozumab represents.